ONCONASE Enters Phase III Pancreatic Clinical Trial

Carmine M. Zingarino gn686 at cleveland.Freenet.Edu
Sat Sep 2 13:37:56 EST 1995

Path: hivnet.org!fido.hivnet.org!aegis.hivnet.org!Mary_Elizabeth
>Newsgroups: hiv.aids.data
Distribution: hivnet
Date: Wed, 25 Jan 95 06:38:39 +0100
From: Mary_Elizabeth at aegis.hivnet.org
Reply-To: Mary_Elizabeth at aegis.hivnet.org
Comment-To: All at f927.n103.z1.fido.hivnet.org
Message-ID: <f26af136 at f927.n103.z1.fido.hivnet.org>
X-Fidonet-Comment-To: Mary_Elizabeth at aegis.hivnet.org
X-FSC-PATH: 103/927 280/413
Lines: 26

      Document 165
 DOCN AD950165
 TI   "ONCONASE Enters Phase III for Pancreatic Cancer"
 DT   950124
 SO   Business Wire (01/24/95)
 AB   Alfacell Corp. announced on Tuesday that it will commence Phase III
      clinical trials for ONCONASE, which is being tested in combination
      with tamoxifen to treat pancreatic cancer.  The FDA approved the
      company's Phase III protocol design--which calls for a randomized,
      multi-center trial--on Jan. 23.  ONCONASE has been established as a
      novel enzyme in both structure and function, and is now recognized as
      the smallest known member of the superfamily of pancreatic
      ribonucleases.  Alfacell is also working with the National Institutes
      of Health to study promising anti-viral activity exhibited by
      ONCONASE in in vitro tests against HIV-1. A study recently published
      in the Proceedings of the National Academy of Sciences found that
      ONCONASE inhibited HIV in vitro by 99 percent.

      DISTRIBUTED BY GENA/aegis (714.248.2836 * 8N1/Full Duplex): Copyright
      (c) 1995 - Information, Inc., Bethesda, MD.  This information is
      provided by the Centers for Disease Control & Prevention (CDC),
      National AIDS Clearinghouse as a public service.  Noncommercial
      reproduction encouraged.

--- FLAME v1.1
 * Origin: GENA/aegis-San Juan Capistrano, CA - 714.248.2836 (1:103/927)

More information about the Cellbiol mailing list